Crossmark

Exploring drug cost and disease outcome in rheumatoid arthritis patients treated with biologic and targeted synthetic DMARDs in Norway in 2010–2019 – a country with a national tender system for prescription of costly drugs

Crossref DOI link: https://doi.org/10.1186/s12913-021-07425-w

Published Online: 2022-01-10

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Brkic, Alen

Diamantopoulos, Andreas P.

Haavardsholm, Espen Andre

Fevang, Bjørg Tilde Svanes

Brekke, Lene Kristin

Loli, Liz

Zettel, Camilla

Rødevand, Erik

Bakland, Gunnstein

Mielnik, Pawel

Haugeberg, Glenn
License Information

Text and Data Mining valid from 2022-01-10

Version of Record valid from 2022-01-10
More Information

Article History

Received: 20 October 2021

Accepted: 15 December 2021

First Online: 10 January 2022

Declarations

:

: The study was approved by the regional ethical committee (REC 2010/3078). No consent from patients was required by the REC as we only use anonymized data.

: Not applicable.

: The authors declare no competing interests. The authors have no financial interests that could create a potential conflict of interest or the appearance of a conflict of interest concerning the submitted work.

Document is current

Any future updates will be listed below